CTCBIO Inc.

KOSDAQ:A060590 Stock Report

Market Cap: ₩76.5b

CTCBIO Past Earnings Performance

Past criteria checks 3/6

CTCBIO has been growing earnings at an average annual rate of 12%, while the Pharmaceuticals industry saw earnings growing at 12% annually. Revenues have been declining at an average rate of 4.5% per year. CTCBIO's return on equity is 7.6%, and it has net margins of 4.8%.

Key information

11.96%

Earnings growth rate

14.60%

EPS growth rate

Pharmaceuticals Industry Growth11.32%
Revenue growth rate-4.53%
Return on equity7.58%
Net Margin4.75%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • Dec 02

These 4 Measures Indicate That CTCBIO (KOSDAQ:060590) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article • Sep 29

Some Shareholders Feeling Restless Over CTCBIO Inc.'s (KOSDAQ:060590) P/S Ratio

It's not a stretch to say that CTCBIO Inc.'s ( KOSDAQ:060590 ) price-to-sales (or "P/S") ratio of 1x right now seems...
Analysis Article • Mar 15

CTCBIO's (KOSDAQ:060590) Shareholders Are Down 64% On Their Shares

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. But...
Analysis Article • Jan 21

Is CTCBIO (KOSDAQ:060590) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article • Nov 29

Would Shareholders Who Purchased CTCBIO's (KOSDAQ:060590) Stock Five Years Be Happy With The Share price Today?

Statistically speaking, long term investing is a profitable endeavour. But that doesn't mean long term investors can...

Revenue & Expenses Breakdown

How CTCBIO makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A060590 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 26128,7586,11739,4391,620
31 Dec 25123,7693,26840,6711,785
30 Sep 25108,2282,66441,9902,347
30 Jun 25112,222-87844,5172,713
31 Mar 25121,365-4,57048,0402,872
31 Dec 24119,877-5,20649,1113,558
30 Sep 24138,949-16,79449,0433,304
30 Jun 24134,346-16,15446,8733,201
31 Mar 24130,593-13,86344,3783,177
31 Dec 23137,878-15,58842,8612,639
30 Sep 23138,214-8,99942,0782,264
30 Jun 23145,562-6,55441,6292,216
31 Mar 23150,208-3,75840,5462,240
31 Dec 22165,2064,70438,8412,414
30 Sep 22172,99610,07236,2282,932
30 Jun 22167,2353,99035,0713,171
31 Mar 22157,384-2,34533,4223,330
31 Dec 21140,318-7,31831,4213,090
30 Sep 21130,017-8,84330,0643,951
30 Jun 21130,642-4,37628,1133,752
31 Mar 21132,378-17,04527,0313,865
31 Dec 20130,032-19,45827,0003,907
30 Sep 20135,117-20,73326,6652,894
30 Jun 20135,041-23,73326,2762,370
31 Mar 20136,645-13,00627,6432,155
31 Dec 19136,124-13,73925,9892,404
30 Sep 19134,619-15,68130,5502,976
30 Jun 19133,567-13,94832,4003,843
31 Mar 19132,269-10,44032,3964,227
31 Dec 18138,400-9,06135,2784,584
30 Sep 18136,755-18,31835,5324,277
30 Jun 18136,358-20,43535,1056,056
31 Mar 18135,374-18,93334,9865,768
31 Dec 17130,559-20,69835,4685,777
30 Sep 17127,007-10,67930,6687,578
30 Jun 17129,176-5,38329,1857,446
31 Mar 17126,689-4,71327,8057,694
31 Dec 16123,146-2,73925,6197,365
30 Sep 16124,4833,79625,6855,708
30 Jun 16116,79664525,4384,127
31 Mar 16115,2961,15825,1734,291
31 Dec 15118,9912,74026,3154,930
30 Sep 15118,32155927,7355,360
30 Jun 15120,9612,71128,3715,574

Quality Earnings: A060590 has high quality earnings.

Growing Profit Margin: A060590 became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A060590 has become profitable over the past 5 years, growing earnings by 12% per year.

Accelerating Growth: A060590 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: A060590 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (25.5%).

Return on Equity

High ROE: A060590's Return on Equity (7.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 15:39
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CTCBIO Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
JongHoon LeeDaishin Securities Co. Ltd.
Al Eum LeeiM Securities
Jae Hoon ShinLS Securities Co., Ltd.